PLSE Rises on Strong Cardiac Catheter Trial Results

Study Highlights Key Success Metrics

Pulse Biosciences (NASDAQ:PLSE) stock increased after the company revealed positive data from its nPulse Cardiac Catheter System feasibility study. The results for treating atrial fibrillation showed 100 percent procedural success in evaluable patients at six months and 96 percent success at 12 months.

These figures demonstrate the system's high level of effectiveness and durability in a clinical setting, representing a significant milestone for the company.

A Closer Look at the Trial Data

The first-in-human study involved a total of 165 patients across nine investigators in Europe. The data highlighted the system's efficiency, with average total procedure times of only 65 minutes.

Additionally, the nPulse system established a strong safety profile. Just 1.3 percent of subjects experienced serious adverse events related to the primary safety endpoint, a critical measure for new medical technologies.

Market Reaction and Future Outlook

The positive clinical data was met with investor confidence, causing PLSE shares to rise. Medical experts described the results as an important step forward, suggesting the system could considerably advance atrial fibrillation treatment.

Pulse Biosciences now plans to begin its pivotal IDE study, treating additional patients in Europe and the United States to further validate its proprietary Nanosecond Pulsed Field Ablation technology.

Summary of Findings

The initial data strongly supports the nPulse system's potential as a safe, effective, and rapid treatment for atrial fibrillation. The market has reacted favorably, and future pivotal trials will be a key catalyst for the company's valuation.

FAQ

Q: What is the nPulse Cardiac Catheter System?
A: It is a medical device from Pulse Biosciences that uses Nanosecond Pulsed Field Ablation energy to treat atrial fibrillation.

Q: What were the key results of the study?
A: The study reported high procedural success rates of 100% at 6 months and 96% at 12 months, alongside a strong safety profile.

Q: How did the market react to the news?
A: Pulse Biosciences stock (NASDAQ:PLSE) rose following the announcement of the positive study data.

Source: Investing.com